In vivo isolation of circulating tumor cells from peripheral blood of patients with breast cancer by using a structured antibody-coated nanodetector: an explorative mono-centre non-randomised trial

GILUPI GmbH (Germany)0 个研究点目标入组 78 人开始时间: 2012年1月11日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Subjects suffering from breast cancer (diagnosed), they are qualified for radical operation of the tumor
•2. Age = 18 years
•3. Results of laboratory tests are in the area that the patient is qualified to perform an operation
•4. Written informed consent

•1. All results of laboratory tests which represent in the opinion of the auditor a risk to the participation of the patient
•2. Different types of allergies (including hay fever)
•3. Anaphylactic or anaphylactoid reactions
•4. Each of the following autoimmune diseases: antiphospholipid syndrome (lupus anticoagulant), goodpasture's syndrome, lupus erythematosus, recurrent polychondritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, anti-neutrophil cytoplasmic antibodies (ANCA)
•5. All forms of immune deficiency: X-linked agammaglobulinemia (XLA), severe combined
•immunodeficiency (SCID), common variable immunodeficiency (CVID), the lack of immunoglobulin A
•6. Serological diagnosis: hepatitis A, B and C, human immunodeficiency virus (HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), syphilis (Wassermann positive test), toxoplasmosis, tuberculosis
•7. Laboratory abnormalities of patients with a negative performance for the surgery
•8. Detectable inflammatory responses

发起方

GILUPI GmbH (Germany)